← Back to Screener
Align Technology Inc (ALGN)
Price$191.66
Favorite Metrics
Price vs S&P 500 (26W)42.35%
Price vs S&P 500 (4W)0.26%
Market Capitalization$13.75B
P/E Ratio (Annual)33.51x
All Metrics
P/CF (Annual)23.18x
Book Value / Share (Quarterly)$56.74
P/TBV (Annual)2.83x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)2.61%
Cash Flow / Share (Quarterly)$6.88
Price vs S&P 500 (YTD)17.58%
Gross Margin (TTM)68.27%
Net Profit Margin (TTM)10.17%
EPS (TTM)$5.66
10-Day Avg Trading Volume0.85M
EPS Excl Extra (TTM)$5.66
Revenue Growth (5Y)10.30%
EPS (Annual)$5.65
ROI (Annual)10.13%
Gross Margin (Annual)68.27%
Net Profit Margin (5Y Avg)12.29%
Cash / Share (Quarterly)$15.34
P/E Basic Excl Extra (TTM)33.51x
Revenue Growth QoQ (YoY)5.26%
EPS Growth (5Y)-24.09%
P/E Normalized (Annual)33.51x
ROA (Last FY)6.58%
Revenue Growth TTM (YoY)0.90%
EBITD / Share (TTM)$11.11
ROE (5Y Avg)12.94%
Operating Margin (TTM)13.53%
Cash Flow / Share (Annual)$6.88
P/B Ratio3.40x
P/B Ratio (Quarterly)2.77x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.14x
Net Interest Coverage (TTM)38.91x
ROA (TTM)6.62%
EPS Growth QoQ (YoY)36.52%
EV / EBITDA (TTM)15.71x
EPS Incl Extra (Annual)$5.65
Current Ratio (Annual)1.36x
Quick Ratio (Quarterly)1.21x
3-Month Avg Trading Volume1.18M
52-Week Price Return13.69%
EV / Free Cash Flow (Annual)25.82x
P/E Incl Extra (TTM)33.51x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$55.42
P/S Ratio (Annual)3.41x
Asset Turnover (Annual)0.65x
52-Week High$208.31
Operating Margin (5Y Avg)17.68%
EPS Excl Extra (Annual)$5.65
CapEx CAGR (5Y)-7.94%
Tangible BV CAGR (5Y)4.97%
26-Week Price Return51.10%
Quick Ratio (Annual)1.21x
13-Week Price Return12.31%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.36x
Enterprise Value$12,670.093
Revenue / Share Growth (5Y)12.24%
Asset Turnover (TTM)0.65x
Book Value / Share Growth (5Y)6.72%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)5.33x
Pretax Margin (Annual)14.51%
Cash / Share (Annual)$15.34
3-Month Return Std Dev45.51%
Gross Margin (5Y Avg)70.63%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)11.44%
EBITDA Interim CAGR (5Y)2.78%
ROE (Last FY)10.13%
Net Interest Coverage (Annual)15.41x
EPS Basic Excl Extra (Annual)$5.65
P/FCF (TTM)28.01x
Receivables Turnover (TTM)3.85x
EV / Free Cash Flow (TTM)25.82x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$5.66
Receivables Turnover (Annual)3.85x
ROI (TTM)10.45%
P/S Ratio (TTM)3.41x
Pretax Margin (5Y Avg)17.60%
Revenue / Share (Annual)$55.59
Tangible BV / Share (Annual)$55.42
Forward P/E16.97x
Free OCF CAGR (5Y)-0.66%
Price vs S&P 500 (52W)-21.40%
P/E Ratio (TTM)33.51x
EPS Growth TTM (YoY)0.86%
Year-to-Date Return21.72%
5-Day Price Return5.20%
EPS Normalized (Annual)$5.65
ROA (5Y Avg)7.95%
Net Profit Margin (Annual)10.17%
Month-to-Date Return10.87%
Cash Flow / Share (TTM)$6.55
EBITD / Share (Annual)$11.11
EPS Growth (3Y)7.02%
Operating Margin (Annual)13.53%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)23.18x
ROI (5Y Avg)12.94%
P/E Excl Extra (TTM)33.51x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$5.66
P/TBV (Quarterly)2.83x
P/B Ratio (Annual)2.77x
Inventory Turnover (TTM)5.33x
Pretax Margin (TTM)14.51%
Book Value / Share (Annual)$56.74
Price vs S&P 500 (13W)9.45%
Net Margin Growth (5Y)-32.36%
Beta1.77x
P/FCF (Annual)28.01x
Revenue / Share (TTM)$56.27
ROE (TTM)10.45%
52-Week Low$122.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.87
3.88
3.92
3.96
Industry Peers — Orthopedic & Prosthetic Devices(25)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
ALGNAlign Technology Inc | 3.41x | 10.30% | 68.27% | 13.53% | $191.66 |
ISRGIntuitive Surgical Inc. | 16.54x | 18.22% | 66.00% | 29.27% | $465.60 |
EWEdwards Lifesciences Corp | 7.77x | 6.70% | 78.01% | 18.41% | $81.44 |
STESTERIS plc | 3.81x | 12.49% | 44.11% | 17.03% | $226.41 |
ZBHZimmer Biomet Holdings, Inc. | 2.31x | 3.22% | 69.71% | 13.34% | $95.48 |
SNNSmith & Nephew plc | 2.37x | 6.21% | 68.01% | 12.88% | $34.21 |
MSAMine Safety Incorporated | 3.60x | 6.82% | 46.46% | 19.83% | $173.50 |
ESTAEstablishment Labs Holdings Inc. | 9.30x | 20.04% | 69.32% | -18.48% | $66.93 |
ENOVEnovis Corporation | 0.68x | -6.05% | 58.16% | -50.09% | $26.27 |
CDRECadre Holdings, Inc. | 2.19x | 8.57% | 42.54% | 11.04% | $30.51 |
AVNSAvanos Medical, Inc. | 1.64x | -0.38% | 50.47% | -8.78% | $24.64 |
About
Align Technology dominates the clear aligner market with Invisalign, which controls over 90% market share since FDA approval in 1998 and can treat approximately 90% of malocclusion cases. The platform has achieved significant scale with 14+ million cumulative patients and treated over 2 million cases in 2022 alone. The company strengthens its ecosystem with iTero intraoral scanners, which capture digital impressions for over half of Invisalign treatments.